acquired
Stage
1
Investors
About
Firefly Bio, Inc. is a biotechnology company developing a proprietary Firelink™ degrader antibody conjugate platform designed to selectively degrade proteins in tumor cells, aiming to treat KRAS-driven and other hard-to-treat solid cancers.
Explore Firefly Bio, Inc.'s full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.